Search for: "State v. Price" Results 3281 - 3300 of 11,955
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
17 Oct 2019, 8:18 am by John Jascob
Created under New Rule 610T of Regulation NMS, the pilot subjects exchange transaction-fee pricing, including "maker-taker" fee-and-rebate pricing models, to new temporary pricing restrictions across three test groups. [read post]
19 Feb 2012, 6:57 pm by A. Brian Albritton
The Blog of Legal Times recently featured an interesting case where a District Court Judge refused after the trial of a False Claims Act ("FCA") case to impose the minimum $50.2 million Civil False Claims Act penalty on the grounds that the penalty was unconstitutionally excessive in violation of the 8th Amendment:  United States ex rel Kurt Bunk & Daniel Heuser v. [read post]
29 Nov 2006, 2:55 pm
After Monday's argument in Bell Atlantic Corp. v. [read post]
21 Mar 2011, 3:07 am by tom
UNITED STATES 09-11556    TOLENTINO, JOSE v. [read post]
3 Jun 2008, 8:51 am
Case Name: Wyoming Bd. of Land Commissioners v. [read post]
3 Aug 2017, 4:47 am by SHG
The Supreme Court’s decision in Regents of the State of California v. [read post]
3 Aug 2017, 4:47 am by SHG
The Supreme Court’s decision in Regents of the State of California v. [read post]
21 Jun 2023, 12:28 pm by Josh Blackman
The post Justice Stevens's Papers Reveal How The Fortune Cookies Were Baked In <I>Lawrence v. [read post]
17 Dec 2021, 7:23 am by Second Circuit Civil Rights Blog
While the Public Health Law contains no provision allowing people to sue the medical provider for price gauging, the state can impose a civil penalty for these violations, up to $2,000 for each violation. [read post]
14 Nov 2008, 6:46 pm
The Court also agreed to decide whether the Constitution requires an elected state judge to step aside from deciding a case involving the financial interests of a major campaign donor (Caperton v. [read post]
17 Sep 2014, 9:24 am
 The launch of generics pre-patent expiry is a substantial threat to innovators given the dramatic price spiral following the first launch (see commentary in SmithKline Beecham v Apotex). [read post]